Skip to main content

Tackling Challenges in Oncology Drug Discovery and Development

Monday, February 26, 2024
Majestic Complex
A recent IQVIA Institute report forecasts that spending on cancer medicines is expected to reach $375Bn globally by 2027, up from $196Bn in 2022. As companies seek to bring these therapies to market and investors make decisions about what to fund, this discussion will provide insights from clinical stage companies and investors along with regulatory considerations on how to contribute to better outcomes for patients.
Asthika Goonewardene, Managing Director, Equity Research - Truist Securities
Johanna Bendell, Global Head of Pharma Research and Early Development Oncology - Roche
Kate Haviland, CEO - Blueprint Medicines
John Oyler, CEO - BeiGene
Lynn Seely, President and CEO - Lyell Immunopharma

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.